Deutsche Bank cuts Diasorin to 'sell', sees company targets as stretched
BUZZ-Deutsche Bank cuts Diasorin to 'sell', sees company targets as stretched ** Deutsche Bank downgrades Diasorin DIAS.MI to "sell" from "hold" on risks of 2026 guidance cut and stretched mid-term goals
** The brokerage says "consensus underestimates the risk of a 2026 guidance cut, alongside overly ambitious assumptions embedded in the company's mid-term growth framework for the LIAISON NES platform"
** DB notes the diagnostic company projects a significant growth acceleration in 2026, but says many of Diasorin's underlying assumptions are inconsistent with peer commentary
** It also lowers TP to €58 from €62, says it expects the share price to underperform its peers as expectations reset
** Of 14 analysts covering Diasorin, five rate it "buy" or "strong buy", seven "hold" and two rate it "sell" - LSEG data
(Reporting by Anna Uras)
Recent news on Diasorin
See all newsEquita upgrades Diasorin, sees 'solid' Q3
Brief: Diasorin Obtained FDA Approval For Fully Automated Laboratory Serology Tests For Human Parvovirus B19 Igm And Human Parvovirus B19 Igg On The Liaison Xl
Europe Research Roundup: Allianz, Mercedes-Benz, Tesco
European life sciences stocks rise on strong sector momentum
Italy - Factors to watch on September 21